From Bench To Bedside, Another Practice-changing Treatment Is On The Road!

12 Mar, 2021

Dr. Rajesh Bollam

Image
From bench to bedside, another practice-changing treatment is on the road!
🔶The oral HIF-2 α inhibitor Belzutifan in patients with advanced ccRCC previously treated with a median of the previous 3 lines!
🔶ORR 25%
🔶SD 55%,
🔶DCR (CR+PR+SD) 80%.
🔶mDOR NR

Add a comment